NJ S4601

Drug manufacturers and wholesale drug distributors are exempted from pharmacist licensing requirements when distributing dialysate drugs and devices for home dialysis to patients with end-stage renal disease

Dialysate drugs and devices must be FDA-approved, held by properly registered entities, and delivered in original sealed packaging from the manufacturing facility

Delivery must occur only upon receipt of a physician's order and can only go to the patient, patient's designee, or a health care provider/institution for dialysis therapy administration

Manufacturers must contract with a board-registered consultant pharmacist to provide weekly quality assurance assessments of home dialysis drug storage and distribution

The bill takes effect on the first day of the third month following enactment